1. Merck Sharp & Dohme LLC. WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf. Accessed 21 May 2024.
2. Nabeh OA, Saud AI, Amin B, et al. A systematic review of novel therapies of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2024;24(1):39–54.
3. Merck Sharp & Dohme. FDA approves Merck's WINREVAIR(Tm) (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO* Group 1) [media release]. 26 Mar 2024. http://www.merck.com.
4. Merck. Our pipeline at a glance. 2024. https://www.merck.com/research/product-pipeline/. Accessed 21 May 2024.
5. Celgene Corporation. Acceleron Pharma announces global collaboration with Celgene Corporation on ACE-011 program for cancer-related bone loss [media release]. 21 Feb 2008. http://www.celgene.com.